首页> 外文期刊>Peritoneal dialysis international: Journal of the International Society for Peritoneal Dialysis >Efficacy of a low-dose intravenous iron sucrose regimen in peritoneal dialysis patients.
【24h】

Efficacy of a low-dose intravenous iron sucrose regimen in peritoneal dialysis patients.

机译:低剂量静脉内蔗糖铁蔗糖疗法在腹膜透析患者中​​的疗效。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: Sufficient iron substitution leads to a decrease in the required recombinant human erythropoietin (rHuEPO) dose and/or an increased hematocrit in dialysis patients. Intravenous (i.v.) application of larger doses of iron sucrose may be associated with hyperferritinemia, appearance of catalytically free iron, and impaired phagocyte function. Therefore, we investigated the effectiveness of a low-dose i.v. iron regimen in peritoneal dialysis (PD) patients. PATIENTS AND INTERVENTIONS: Forty-five PD patients were followed over a period of 1 year. Serum ferritin, serum transferrin saturation, and hemoglobin were measured monthly. In cases of absolute iron deficiency (serum ferritin < 100 microg/L), 50 mg iron sucrose was given i.v. every second week. In cases of functional iron deficiency (ferritin > or = 100 microg/L and transferrin saturation < 20%) and in iron repleted patients (ferritin > or = 100 microg/L and transferrin saturation > or = 20%), 50 mg i.v. iron sucrose was applied monthly. Iron therapy was stopped in cases of acute infection (until complete recovery) and when serum ferritin level was > or = 600 microg/L. RESULTS: To analyze the influence of iron substitution on erythropoiesis and rHuEPO requirements, the EPO resistance index (ERI; quotient of rHuEPO dose in units/kilogram/week and hemoglobin in grams per deciliter) was calculated every 3 months. The ERI decreased significantly during the course of the study in the whole patient group (p = 0.009) as well as in the subgroup of 21 patients with absolute iron deficiency (p = 0.01). A nonsignificant decrease in the ERI was observed within the group of 14 iron repleted patients (p = 0.5). There was no significant change in the ERI in 10 patients with functional iron deficiency (p = 0.6). CONCLUSION: The low-dose i.v. iron regimen used in this study substantially decreased rHuEPO requirements in patients with absolute iron deficiency and was effective in maintaining iron stores in iron repleted patients. However, in the absence of significant hyperparathyroidism, aluminum toxicity, or inadequate dialysis, it did not improve the ERI in patients with functional iron deficiency.
机译:目的:充足的铁替代导致透析患者所需的重组人促红细胞生成素(rHuEPO)剂量减少和/或血细胞比容升高。静脉内(静脉内)应用较大剂量的蔗糖铁可能与高铁蛋白血症,催化性游离铁的出现以及吞噬细胞功能受损有关。因此,我们研究了低剂量静脉输注的有效性。腹膜透析(PD)患者的铁疗法。患者与干预措施:1年内对45例PD患者进行了随访。每月测量血清铁蛋白,血清转铁蛋白饱和度和血红蛋白。如果绝对缺铁(血清铁蛋白<100微克/升),则静脉内给予50 mg蔗糖铁。每隔第二周。在功能性铁缺乏症(铁蛋白>或= 100 microg / L且转铁蛋白饱和度<20%)的情况下和补铁的患者中(铁蛋白>或= 100 microg / L且转铁蛋白饱和度>或= 20%),静脉内50 mg。每月施用蔗糖铁。如果发生急性感染(直到完全恢复),并且血清铁蛋白水平>或= 600 microg / L,则停止铁治疗。结果:为了分析铁替代对红细胞生成和rHuEPO需求的影响,每3个月计算一次EPO抵抗指数(ERI; rHuEPO剂量的单位/千​​克/周和血红蛋白的克数/分升的商)。在研究过程中,整个患者组(p = 0.009)以及21个绝对铁缺乏症患者亚组(p = 0.01)的ERI均显着降低。在14名铁补充的患者组中,ERI无明显下降(p = 0.5)。 10名功能性铁缺乏症患者的ERI没有显着变化(p = 0.6)。结论:小剂量静脉注射这项研究中使用的铁疗法显着降低了绝对铁缺乏症患者的rHuEPO需求量,并有效地维持了铁补充患者的铁存储。然而,在没有明显的甲状旁腺功能亢进,铝毒性或透析不足的情况下,它不能改善功能性铁缺乏症患者的ERI。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号